Christie L. Eissler

Christie L. Eissler

Auto-generated profile, based on publicly available information

Christie L. Eissler

Vividion Therapeutics, San Diego, California

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2026 in Cancer Discovery
Verified
Journal Article
Open access
NRNilotpal Roy
Nilotpal Roy
TWTine Wyseure
Tine Wyseure
ILI-Chung Lo
I-Chung Lo
JLJustine Lu
Justine Lu
CEChristie L. Eissler
Christie L. Eissler
MPMatthew P. Patricelli
Matthew P. Patricelli
The NRF2 transcription factor is constitutively active in cancer, in which it functions to maintain oxidative homeostasis and reprogram cellular metabolism. NRF2-active tumors exhibit NRF2 dependency and resistance to chemotherapy/radiotherapy (RT). In this study, we characterize VVD-065, a first-in-class NRF2 inhibitor that acts via an unprecedented allosteric molecular glue mechanism. In the absence of stress or mutation, NRF2 is rapidly degraded by the Kelch-like ECH-associated protein 1 (KEAP1)–cullin3 (CUL3) ubiquitin-ligase complex. VVD-065 specifically and covalently engages Cys151 on KEAP1, which in turn promotes KEAP1–CUL3 complex formation, leading to enhancement of NRF2 degradation. Previously reported Cys151-directed compounds decrease KEAP1–CUL3 interactions and stabilize NRF2, thus establishing KEAP1C151 as a tunable regulator of the KEAP1–CUL3 complex and NRF2 stability. VVD-065 inhibited NRF2-dependent tumor growth and sensitized cancers to chemotherapy/RT, supporting an open phase I clinical trial (NCT05954312). Significance: NRF2 hyperactivation is frequently observed in various solid tumors, including lung, esophageal, and head and neck cancers, highlighting NRF2 as a potential therapeutic target. We report a first-in-class KEAP1-dependent allosteric molecular glue degrader of NRF2, which demonstrated robust monotherapy responses in NRF2-activated cancers and effectively sensitized chemo-refractory tumors to chemotherapy. See related commentary by Hintzen and Burslem, p. XX

17 June 2026
Verified
Other
Open access
NRNilotpal Roy
Nilotpal Roy
TWTine Wyseure
Tine Wyseure
ILI-Chung Lo
I-Chung Lo
JLJustine Lu
Justine Lu
CEChristie L. Eissler
Christie L. Eissler
MPMatthew P. Patricelli
Matthew P. Patricelli
Shows the anti-proliferative activity of VVD-065, observed across various cell lines and potentiated in 3D culture, is fundamentally linked to the presence of KEAP1 Cys151


17 June 2026
Verified
Other
Open access
PDF file
NRNilotpal Roy
Nilotpal Roy
TWTine Wyseure
Tine Wyseure
ILI-Chung Lo
I-Chung Lo
JLJustine Lu
Justine Lu
CEChristie L. Eissler
Christie L. Eissler
MPMatthew P. Patricelli
Matthew P. Patricelli
Shows synthesis routes of compounds

17 June 2026
Verified
Other
Open access
PDF file
NRNilotpal Roy
Nilotpal Roy
TWTine Wyseure
Tine Wyseure
ILI-Chung Lo
I-Chung Lo
JLJustine Lu
Justine Lu
CEChristie L. Eissler
Christie L. Eissler
MPMatthew P. Patricelli
Matthew P. Patricelli
Shows TGI effects of VVD-065 and NRF2 genetic ablation in a variety of cell line derived xenograft models

17 June 2026
Verified
Other
Open access
NRNilotpal Roy
Nilotpal Roy
TWTine Wyseure
Tine Wyseure
ILI-Chung Lo
I-Chung Lo
JLJustine Lu
Justine Lu
CEChristie L. Eissler
Christie L. Eissler
MPMatthew P. Patricelli
Matthew P. Patricelli
Shows global proteomic analysis of VVD-065 treated cells